MOLN
Molecular Partners AG Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website molecularpartners.com
- Employees(FY) 175
- ISIN US60853G1067
Performance
+2.13%
1W
-3.32%
1M
-16.0%
3M
-16.92%
6M
-9.57%
YTD
-41.85%
1Y
Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; as well as other third-party collaborators. It also has a collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Technical Analysis of MOLN 2024-05-10
Overview:
In analyzing the technical indicators for MOLN stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key indicators, we aim to offer valuable insights and recommendations for potential inves...
Recent News & Updates
- 2023-03-12 12:22
- 2023-03-10 13:14
- 2023-03-09 03:00
- 2023-03-02 03:00
- 2023-02-27 12:15
- 2023-02-09 12:00
- 2023-01-15 12:00
- 2023-01-11 17:18
- 2023-01-08 02:00
- 2022-12-29 12:00
- 2022-12-12 06:00
- 2022-12-01 10:46
- 2022-11-09 12:00
- 2022-11-03 21:39
- 2022-11-03 00:30
- 2022-11-02 00:30
- 2022-10-27 04:00
- 2022-10-27 04:00
- 2022-08-25 04:30
- 2022-08-17 13:00
- 2022-07-20 23:30
- 2022-06-09 13:00
- 2022-05-12 04:05
- 2022-05-10 13:00
- 2022-05-03 00:00
- 2022-04-26 20:02
- 2022-04-26 18:01
- 2022-04-26 17:59
- 2022-04-26 04:05
- 2022-04-26 02:00